Index

ACLU DNA patentability litigation 155–9

American Association for the Advancement of Science 131

American Convention on Human Rights (1969) 78

American Fruit Growers 139

Amgen v. Chugai 146–7, 169

amniocentesis 86

animal life
animal-human hybrids 174, 298
bioreactors, use as 47
chimeras 53, 83–4, 124–5, 174, 298
cloning 93–4, 175
genetic research 45–7, 166–7, 225–6

patentability
balance of interests test 220–22, 224–8
EU patent cases 214–19, 226–6
EU patent restrictions 182, 185, 190, 195, 197–8
generally 31, 277

Harvard Onco-Mouse 31, 144, 166–7, 215–21, 224–6

TRIPS Protection 29–30, 32
US patent cases 142–4, 165–7

balance of interests test 220–22, 224–8, 233, 235–6, 255
Bayh-Dole Act (1980, US) 117, 283

Bedford v. Hunt 122

bio-law
see also bioethics
human cloning, and 95–7
interpretations of 50–51, 53–5

bioethics
see also European Union; United States
animal life, patentability of animal-human cloning hybrids 174
balance of interests test 220–22, 224–8
patent cases 49, 53–4, 142–4, 165–7, 215–19, 224–6
background 49, 53–4
Catholic bioethics 12, 172–3
definition 11–12, 50
economic efficiency, and 51–2
evolutionary theory, and 51
gene therapy, and 63–5, 167–75
human cloning 95–7, 101–6, 173–5
human dignity, and 52–3, 68, 80–81, 256–8, 297, 303
human embryos
creation of defects in 135
destruction of 131, 233–6, 240
embryonic stem cells 169–73, 230–42
interpretations of 50–51, 53–4
liberalism, need for 293
microorganisms, patentability of 165, 213–15, 224
transgenic humans 174

Biogen v. Medeva 221–2
bioreactors 3, 47

biotechnology, generally
applied research vs. pure research 284–5
benefits 9, 298
common heritage of mankind 67, 69–71, 296–7
composition of matter, as 137, 139–40
definitions 1–2
biotechnological inventions and patentability of life

ethics and morality of 298
animal research 45–7, 166–7, 225–6
arguments against 31, 43–5
compatibility conflicts 39
economic efficiency, and 51–2
freedom, interpretation of 50–51
human dignity, and 52–3, 68, 256–8, 297, 303
implications 9, 11
patentability conflicts 31
personal views on 52–3
pragmatist-utilitarian views 51–2
reductionist-evolutionist views 51
research role, interpretations of 49–52
scientific-radical views 50–51
human uses 62–3
implications of 5, 45–9
isolation and purification 61, 137–41, 153–64, 277–8
legal challenges 12, 261–2
manufacture, relevance of 139–41
patent regime, and
barrier patents 250, 284–5
challenges for 248–51, 262
definitions proposal 253
interpretation inconsistencies 254–5
mixed system, benefits of 302
risk and threats 45–9
traditional vs. innovative biotechnology 2
TRIPS Agreement protections 29–32, 306–8
biotechnology patents, generally
see also genetic patents
advisory bodies, influences of 266–9
barrier patents 250, 284–5
case law, influences on 263–4, 266–7
challenges 6, 8–9, 248–51, 261–2
clearing houses 291
compulsory licensing 287–8
cooperation mechanisms, value of 287–91
definitions proposal 253
fair use access proposals 285–6
human intervention requirement 7–8, 32, 43–4
humanistic and other scientific disciplines, relationship with 259, 262–3
immoral patents, and 294–7
innovation challenges 284–6
interpretation inconsistencies 254–5
judicial influences on 7, 19, 138–41, 151, 165, 276–7
morality objections 294–7
open source model for 291–2
patent pools 290
political influences 258–61, 265, 270, 275
product of nature doctrine 7, 20–21, 33, 196, 276–81, 295–7
EU patent regime 188–9, 195
US patent regime 138–41, 161–4, 276–81
product protection, conflicts 281–2
proprietary model for 292
purpose 6–7, 43–4, 249
regime development, influences on 264–5
regulatory challenges 9–11, 248, 253–4, 262
Safe Harbor Principles, proposal 308–9
social objectives 295
technological challenges 9–11
theological objections 296
third party access proposals 285–6
trends 7
TRIPS Agreement, importance of 34, 264, 286–7, 306–8
US patent regime limitations 282–3, 304–6
bone marrow stem cells 86–7
Boyer, H. 3, 145
BRCA1 and BRCA2 patent applications 78–80, 89–91, 130–35, 172–3

Andrea Stazi - 9781784715908
Downloaded from Elgar Online at 05/25/2019 02:26:58PM
via free access
Index

Breast and Ovarian Cancer/University of Utah patent application 228–9
breast cancer genes, patentability 155–9, 162–4, 228–9, 278–80
Brenner v. Manson 122, 152
Catholic bioethics 12, 172–3
cDNA (complementary DNA) 59–60, 123–4, 279–80
cellular cloning 93
on human cloning 100
on human dignity 80–81, 202–5
importance of 204–5, 300–302
on right to life 80–81
chemical substances 23, 32–3
chimeras 53, 83–4, 124–5, 174, 298
chromosomes 56–7
cloning
animal life 93–4, 174–5
definition 93–4
 genetic modification, and 60–61
human cloning 53, 66–8
 admissibility 95, 104
 animal-human hybrids 174
 bioethics 95–7, 101–6, 173–5
 EU regulatory restrictions 99–100, 105–6, 210
 genetic identity, right to 101–2
 human life, protection of 96
 individuality, risks to 96–7, 99, 101–2
 legal considerations 100–104, 107–8
 potential uses and benefits 95
 processes 93–4
 prohibition 95–100, 103–4, 106–8, 173
 regulatory restrictions 97–9, 97–100, 119, 174–5
 reproductive cloning 94, 100–104, 106–8
 stem cells 94–5, 105
 therapeutic cloning 94–5, 104–7
 US regulatory restrictions 98–9, 103–4, 119, 173–5

in vitro fertilization 105–6
plant life 93
 processes 59–61, 93–4
 prohibition 95–100, 103–4, 106–8, 173
 recombinant DNA, and 59–60
Cohen, S. 3, 145
Commission v. Italy 194
common heritage of mankind 67, 69–71, 296–7
comparative method
basis of 258–61
benefits of 261–3
biotechnology patent law and other scientific disciplines 261–3
intellectual property, general interpretation role 260–61
Constitution for the Protection of Intellectual Property (1883) 178–9
Constitution for the Protection of New Varieties of Plants (UPOV) (1961) 182
Constitution on Patents for Invention (1963) 18, 179–81, 184
Constitution on the Rights of the Child (1989) 77
creative destruction 275
Declaration of the Rights of the Child (1959) 77
diagnostic treatment methods
breast cancer genes, patentability 155–9, 162–4, 228–9, 278–80
DNA/ genetic material, patentability of 154–64
medical utility exception 206, 229
patent exclusions 31, 126, 195, 199
Dickey-Wicker amendment (US) 78–9, 89, 134, 173
dignity see human dignity
Directive on Biotechnological Inventions 8–9, 186–7, 298–9
adoption 187, 189
compliance requirements 196
drafting challenges 188–9
Biotechnological inventions and patentability of life

exclusions 188–9, 196–7
human dignity, protection of 193, 201–3
human rights, and 201–6
implementation 192, 194
importance 192
interpretation challenges 196–8
legal validity of 192–4, 200
limitations 196–8, 200
minimum standards 303
morality influences on 187–8, 191, 193–4, 199–201
principles 187–90
purpose 193
TRIPS Agreement protections, compared 190–91
disclosure requirement 27–9, 115
discovery
upstream discoveries 284–5
vs. invention 19–22, 180–81, 193, 209, 256
DNA
background 2–5
cDNA (complementary DNA) 59–60, 123–4, 279–80
cloning 59–61
Expressed Sequence Tags (EST) 69, 125, 149–51
extraction processes 58
fragmentation 58–9
human genome mapping 4–5
open access approach 145
origin of replication sequence 58–9
patentability
bioethics of 167–75
cDNA 123–4, 279–80
commoditization, and 297, 301
creation of new entity requirement 146–7, 276–7
EST 69, 125, 149–51
EU patent cases 220–23, 227–8
EU patent restrictions 207–13
exclusions 32–3
genetic sequences 148–52, 207–9
genetic treatments and tests 154–64
isolated and purified materials 7, 19, 138–41, 151, 165, 210–13, 276–8
isolation and incorporation processes 153–9, 210–13
monoclonal antibodies 153–4
moral utility doctrine 123–5
non-absolute protections 208–9
non-obviousness 147
novelty requirement 210
patent ownership sharing 147–8
Trilateral Cooperation initiative 151
US patent cases 145–64
utility requirement 149–51, 207–9
recombinant DNA 2–3, 59–61
structure 56–7
Dolly the sheep 94
Dulbecco, R. 91–2
Dworkin, R. 75–6
Edinburgh Patent application 230–32
Eisma, D. 230
embryos see human embryos
ethics, generally
see also bioethics; morality
law as ethical concept 294
pragmatist-utilitarian views 51–2
reductionist-evolutionist views 51
scientific-radical views 50–51
eugenics 96–7, 301
European Convention on Human Rights and Biomedicine (1999) 68, 81
on human cloning 99–100
on human dignity 201–4, 211–12
on informed consent 212–13
European Group on Ethics in Science and New Technologies advisory function 212–13, 268–9
on human cloning 106–7
European Patent Convention (1973) background 18, 178, 182–3
compliance challenges 197–8
exclusions 200–201, 277
implementation 184
interpretation 200–201
morality, influences of 38–9, 196–7
originality requirement 277
purpose 182–4
regulatory conflicts 199–201
European Union
see also European Patent Convention
bioethics
advisory organizations 268–9
animal life, patentability 215–19, 224–6, 277
breast cancer genes, patentability 155–9, 162–4, 228–9, 278–80
commoditization of life 297, 301
compliance challenges 196–8
diagnosis restrictions 195, 199, 229
DNA, patentability 220–23, 227–8
embryonic stem cells 230–42
embryonic cells, patentability 220–23, 227–8
genetic treatments and tests, patentability of 228–42
human rights and dignity 80–81, 193, 201–5, 210–13, 297, 300–302
human tissue and inventions, patentability 188–90, 193, 199–200, 206–13, 220–22, 227–8
isolated and purified materials 210–13, 276–7
limitations 197–8, 200
medical utility 206
microorganisms, patentability 213–15, 224
morality influences 37–9, 181–2, 185, 187–9, 191, 193–4, 196–206, 218–19, 225–6, 302
patent cases 213–42
public order restrictions 197–206, 218–19, 299
regulatory restrictions 195–6
biotechnology patents
Directive on Biotechnological Inventions 8–9, 186–94, 196–200, 298–9, 303
exclusions 187–91, 196
public order and ethics conflicts 31, 188, 191, 193–4, 196–206, 218–19, 299
human cloning
processes 105–6
regulatory restrictions 99–100, 105–6, 210
human dignity 80–81, 193, 201–5, 210–13, 297, 300–301
human rights
importance of 211, 300–302
right to life 80–81, 300
stem cell research, and 80–83, 89–90
patent cases
animal life, patentability 215–19
balance of interests test 220–22, 224–8, 233, 235–6
biotechnology processes 214–15, 218–19, 281–2
embryonic stem cells 230–42
embryonic cells, patentability of 220–23, 227–8
genetic treatments and tests, patentability of 228–42
importance of 266–7, 272–3
microorganisms, patentability of 213–15, 224
patent regime
advisory bodies, influences of 266–9
animal life restrictions 182, 185, 190, 195, 197–8, 215–19, 277
background 18, 37, 177–80
burden of proof 274
Community patent proposal 177–8
development and amendment 179–80, 265–6
diagnostic methods 195, 199, 228–9
disclosure requirement 27–9
exclusions 35, 180–82, 184–6, 188–91, 195–6, 248
harmonization 182–8
health and life, protection of 180
human dignity, and 193, 201–5, 297
human tissue and inventions, patentability 188–90, 193, 199–200, 206–13
industriality/utility requirement 25, 179–80, 206–9
informed consent requirement 188–9, 212–13, 222, 301
interest groups, influences of 271–3
invention vs. discovery 20–22, 180–81
isolated or purified materials 210–13
judicial rulings, importance of 266–7, 272–3
medical utility 206
morality, influence of 37–9, 181–2, 185, 187–9, 191, 193–4, 196–206, 218–19, 225–6, 302
national differences, implications of 273–4
national treatment principle 179
non-absolute protections 208–9
novelty requirement 22–3, 179–80, 277
ownership limitations 248
Paris Convention 178–9
patent authorities 36
patentability criteria 184, 189–90, 195–6
plant life protections 182, 185, 190, 195, 197–8, 277
political influences on 265, 275
principles 36–7, 179–82, 274
product of nature doctrine 188–9, 195, 276–7
purpose 18, 180
regulatory conflicts 199–201
regulatory restrictions 35, 80–83, 89–90, 180–82, 184–6, 195, 234–6
rights of priority 179
scope of protection 180–81
Sensitive Cases system 299
Strasbourg Convention 18, 179–81, 184
time limits 17–18
US regime, differences from 35–7, 110–11, 121, 263–74, 293, 305–6
stem cells
patent cases 230–42
regulatory restrictions 80–84, 89–90, 230–32, 234–6
TRIPS Agreement
implementation 34–5
Ex parte Allen 142–3, 166
Ex parte Tanksley 123–4
Ex parte Thomas F. Deuel 124
ex vivo gene therapy 62–3
exons 59
Expressed Sequence Tags (EST) 69, 125, 149–51
Federal Technology Transfer Act (1986, US) 118
Fisher v. Lalunghi 152
Funk Brothers Seed Co. v. Kalo
Inoculant Co. 20–21
gene therapy
background 155
bioethics 63–5, 167–75
breast cancer genes 155–9, 162–4, 228–9, 278–80
EU patent regime 195, 228–9
human embryos, and 63–5
justification for 64
limitations 65
patentability 154–64, 195
stem cells, and 63–5
types and uses 62–3
US patent cases 155–64
in vivo tissue engineering 62–5
Genentech-II Polypeptide expression 214–15, 224
genes
see also DNA
cloning 59, 61
gene therapy 62–3
Human Genome Project 4–5, 67–8
Index

isolation and purification
  patentability 148–9, 153–64, 210–13, 277–8
  processes 61, 148–9, 153–9
  novelty requirement 210
  structure 56–7, 59
  transfer of 61–3

generic discrimination 66, 68, 129
  genetic identity
    embryo manipulation 128–9, 230–31
    human cloning, and 101–2
    insurance and employment implications 129
    right to 101–2
  Genetic Information Misdescription Act (2008, US) 129
  genetic modification/ engineering 2–3
    commercial applications 5–6
    human intervention 7–8, 32, 43–4
    human tissue
      gene therapy 62–5
      isolated or purified materials 210–13
      in vivo tissue engineering 62–5
  morality of 9, 43–8, 127–8
  patentability 7, 32, 126–8
    barrier patents 250
    conflicts 8–9, 250
    processes 3, 58–61
    cloning 60–61
    interpretation 45
    patent protection 281–2
    product of nature doctrine 7, 20–21, 33, 138–41, 161–4
    risks 44–8, 224–5
  genetic patents
    bioethics of 167–75, 226–42
    conflicts 8–9
    EU Directive 8–9
    human genome patents 7
    human intervention requirement 7–8, 32, 43–4
    human life, relationship with 227–8
    limitations 6, 32–3
    privacy implications 66
    repugnant uses 66, 96, 199–200, 220–22, 227–8, 308
    TRIPS protections 32–3
  US Patent Office guidelines 8
  genome, structure 57

Germany
  stem cell research restrictions 84, 90
  golden rule 54–5, 75
  Gottschalk v. Benson 19
  Graham v. John Deere Co. 24, 115–16
  Guarani Indian tribe DNA patent application 168–9
  Habermas, J. 75
  Harvard Onco-Mouse 31, 144, 166–7, 215–21, 224–6
  Horizon 2020 Framework Programme for Research and innovation (EU) 82, 89, 105–6
  Hotchkiss v. Greenwood 115
  Howard Florey/Relaxin 220–22, 227–8
  human cloning see cloning
  human dignity
    beginning of life debates
      denial of dignity approach 72–3, 87–8
      support of dignity approach 73–5, 88–9, 238–9
    bioethics, and 52–3, 68, 80–81, 201–5, 297
    human embryos, and 72–3, 76–7, 79–80, 238–9
    human rights, and 80–81, 193, 201–5, 300–301
    interpretation 52–3, 119–20
    protection
      degradation prohibition 53
      discrimination prohibition 66, 68, 129
      EU law, and 80–81, 193, 201–5, 210–13, 220–22
      intellectual property law conflicts 256–8, 303
      minimum standards 53
      slavery prohibition 119–20, 174–5
      US constitutional basis for 119–20, 174
  stem cell research 76–7, 238–9
  human embryos
    see also cloning; stem cells
amniocentesis 86
beginning of life debates 71–6
death, definition of 91, 133
denial of dignity approach 72–3, 87–8
destruction of embryos 131
functionalist theories 73
legal capacity doctrine, and 72–3
legal status 71–2, 76–7, 83–5
philosophical approaches 75–6
rationalist theories 73–4
right to life, and 80–81, 88–9, 129
Roman Law 71–2
support of dignity approach 73–5, 88–9, 238–9
cryopreservation 71–2, 84, 169–70
definition 78–9, 237–9, 240–41, 303
gene therapy, and 63–5
human dignity, and 72–3, 76–7, 79–80, 238–9
research
creation of defects in 135
destruction of embryos 131, 233–6, 240
diagnosis or therapy uses 76–7, 87–8, 90–91
embryo manipulation 128–9, 230–31
embryo splitting 93
ethical conflicts 87–8
frozen embryos, bioethics of 169–70
informed consent 212–13
legal conflicts 76–7
prenatal diagnosis and intervention 71–2
regulatory restrictions 78–82
right to life, and 80–81, 88–9, 91–2, 133
risk to mother, and 81–2
human genome
see also stem cells
common heritage of mankind, as 67, 69–71, 296–7
genetic discrimination, and 66, 68, 129
mapping 4–5
patents on 7, 126–7
privacy implications 66
public asset, as 43–4, 48
research
diagnostic implications 57–8, 66, 229
human/primate DNA combining 66–7
human dignity, and 68
human embryos 71–85
informed consent 66–8, 92, 212–13, 222, 228–9, 301
intellectual property conflicts 68–9
legal and ethical implications 66–82
limitations 66–71, 85–92
privacy implications 66
public availability 68
reproductive/therapeutic cloning 68, 93–108
Universal Declaration on the
Human Genome and Human Rights (1997) 67–70, 127–8, 277
scientific importance 57–8
structure 56–7
Human Genome Project 4–5, 67–8
human intervention requirement
genetic patents 7–8, 32, 43–4
human life
beginnings of, debates on 71–6
human dignity, and 52–3, 68, 77–8, 201–5, 297
patentability 29–30, 126
sanctity of 75–6
human rights
see also Universal Declaration on the
Human Genome and Human Rights
EU law protections 297, 300–302
advisory institutions 212–13
Directive on Biotechnological Inventions 201–6
human dignity, and 80–81, 193, 201–5, 220–22, 300–301
right to life 80–81, 300
Index

stem cell research, and 80–83, 89–90
human cloning, and 99–100
intellectual property, conflicts with 256–8, 303
human tissue
see also DNA; human embryos; stem cells
gene therapy 62–5
human organs, marketing 130
patentability
balance of interests test 220–22, 224–8, 233, 235–6
bioethics of 167–75
EU regime on 188–90, 193, 199–200, 206–13, 220–22, 227–8
TRIPS protection 29–30
research uses
cloning 53, 66–8, 100–105
consent, and 64–8, 92, 133, 135, 212–13, 222, 228–9
ethical conflicts 87–8
industriality/utility requirement 25–6
legality 65
morality of 47–8
in vivo tissue engineering 62–5
Hybertech Inc. v. Monoclonal Antibodies Inc. 153–4

In re. Bell 147, 169
In re. Bergy, Coats and Malik 138
In re. Deuel 147, 169
In re. Fisher 125
In re. Kabin 255
In re. o Farrell 154, 169
In re. Vaeck 154
In re. Wands 154
in vivo gene therapy 62–5
industriality requirement 18, 24–6
EU patent regime 25, 179–80, 206–9
gene sequences 149–50, 207–9
moral utility doctrine 122–6
US patent regime 115, 121–6
informed consent
EU patent regime 188–9, 212–13, 222, 228–9, 301
human genome research 66–8, 212–13, 222, 228–9
stem cell research 92, 133, 135
innovation
creative destruction, and 275
patent regime, influences on 16–17, 26–7, 243–5, 255, 292
subsequent innovation, patent conflicts 281–2, 284–5
intellectual property, generally
comparative method, role of 260–61
fundamental rights, conflicts with 256–8, 303
overprotection implications 251–2
purpose 14, 294–5
interest groups, influences of 269–73
International Bioethics Committee (UNESCO) 70
International Covenant on Civil and Political Rights (1976) 77
International Covenant on Economic, Social and Cultural Rights (1976) 77
International Stem Cell decision 242, 303
introns 59
invention
definition 19–21
subsequent innovation, and 281–2, 284–5
vs. discovery 19–22, 180–81, 193, 209, 256
inventive step see originality requirement
Italy
stem cell research restrictions 83–4, 90
John Moore patent application 145–6, 167–8
Jonas, H. 55, 96
Biotechnological inventions and patentability of life

Juicy Whip Inc. v. Orange Bang Inc. and Unique Beverage Dispensers Inc. 122–3

Kewanee Oil Company v. Bicron Corp. 112

law of nature, patentability of 19–21, 161–4, 295–7
legal positivism 294
legal process approach
   comparative method 258–61
   definition 260
   patent regime, influences on 258–9
   political influences 260
Lowell v. Lewis 122

Mary Scott Doe. v. US 169–70
Mayo v. Prometheus 160–61, 278–9, 306
medicine, personalization of 8
Merck v. Integra 151–2
Method of Diagnosis/ University of Utah patent application 229
microbiology see microorganisms
microorganisms
   patentability
   bioethics of 165
   EU case law interpretation 190, 213–15
   US case law interpretation 7, 136–41, 165
   risks of 46–8
   Treaty on Deposit of Microorganisms for Patent Procedures (1977) 32–3
   vs. biology, interpretation 32
molecular cloning 93
monoclonal antibodies 153–4
Monsanto v. Cefetra 208–9
morality
   see also bioethics
   animal research, of 45–7, 166–7, 225–6
   definition 11
   influences on
   generally 37

human rights 204–5
   pragmatist-utilitarian 51–2
   reductionist-evolutionist 51
   scientific-radical 50–51
   legal positivism, and 294
   patents, and
   biotechnology, risks of 44–8
   conflicts 16, 36–9
   debate limitations 38
   EU, influences in 37–9, 181–2, 185, 187–9, 191, 193–4, 196–206, 218–19, 225–6, 302
   exclusions 29–30, 126
   externalization of immorality 302
   genetic material 43–4
   human interference conflicts 43–4, 47–8
   moral utility doctrine 122–6
   US, influences in 36–8, 120–26, 298, 304–6
   purpose of 39, 45–6
   responsibility obligations 44–5
mRNA (messenger RNA) 59–60
Mutation/ University of Utah patent application 229
Myriad BRCA gene litigation 155–9, 162–4, 228–9, 278–9, 306
National Bioethics Advisory Committee (US) 131, 267
Netherlands v. European Parliament 192–4
Newman, S. 174, 298, 304
non-discrimination
   TRIPS protections 29–30
   non-obviousness see originality
   requirement
   novelty requirement 11, 18, 22–3, 115, 179–80, 210
   nuclear cloning 94
Oliver Brüstle v. Greenpeace eV. 237–9, 256–7, 303, 306
origin of replication sequencing 58–9
originality requirement 11, 18, 23–4, 179–80, 277
DNA patentability, and 147
erosion of 245–7
obviousness 23–4, 115, 147, 180, 255

Parker v. Flook 20
Parte Veneziana 114–15
Pasteur, L. 136
patent thickets 252, 284–5
patents, generally
see also genetic patents; unpatentable innovations
barrier patents 250, 284–5
biotechnology, challenges for patent regime 248–51, 261–2
changing attitudes to 245–7
clearing houses 291
comparative method, interpretative role of 258–9
conflicts 15–16, 19, 26, 68–9, 251–2, 262–3
correlation mechanisms, value of 287–91
creative destruction, and 275
cross-border business implications 13
diagnostic/surgical methods 31, 126, 195, 199, 229
disclosure requirement 27–9, 115
discovery vs. invention 19–22, 180–81, 193
economic policy, and 39–40, 45, 269–70
evolution of 243–7
exclusions 19–21, 29–31, 126
exclusivity
amendments to 246–7
negative rights of 15–17, 246–7
ownership limitations 247–8
regulatory vs. case law conflicts 247–8
humanistic disciplines, relationship with 259, 262–3
industriality/utility requirement 18, 24–6, 115, 121–2
innovation, influences on 16–17, 26–7, 243–5, 255, 292
interest groups, influences of 269–71
justifications for 39–48

legal process approach 258–60
limitations 17, 29–30
merely technical concept 255
negative consequences 251–2
non-discrimination requirement 29–30
novelty requirement 11, 18, 22–3
originality requirement 11, 18, 23–4, 245–7, 255
patent pools 290
drug thicken 252, 284–5
political influences on 251–2, 258–61, 265, 269–70, 275
product of nature doctrine 7, 20–21, 33, 196, 276–81, 295–7
EU patent regime 188–9, 195
US patent regime 138–41, 161–4, 276–81
product protections 281
public choice theory, and 270
public interest, and 15–17
public order conflicts
EU patent regime 181–2, 185, 188, 191, 193–4, 196–206, 218–19, 299
TRIPS protections 29–31, 126, 307
public policy influences 258–61
regime development, influences on 264
regime variations, implications of 13
scientific disciplines, relationship with 259, 262–3
social costs 249
social objectives 295
stakeholder interests, and 269–70
sui generis systems 246–7
time limits 17
tragedy of anticommons 251–2, 284–5
pharmacogenomics 8
Pioneer Hi-Bred International 173, 175
plant life
cloning 93
EU patent restrictions 182, 185, 190, 195, 197–8, 277

genetic research, risks of 46

plant varieties protection 182, 213

TRIPS Protection 29–32

Presidential Commission for the Study of Bioethical Issues (US) 128, 268

President’s Council on Bioethics (US) 128–9, 267–8

prior art see originality requirement

process protection

EU patent case interpretation 214–15, 218–19

TRIPS Agreement treatment 32

US patent case interpretation 153–64, 210

product of nature doctrine 7, 20–21, 33, 196, 276–81, 295–7

EU patent regime 188–9, 195

US patent regime 138–41, 161–4, 276–81


public choice theory 270

public health

TRIPS protections 29–31, 287, 308

public interest

human embryos, and right to life 129

patents, conflicts with 15–17, 138

TRIPS protection 29–31, 126, 287

public order

legal purpose, and 294–5

patentability exclusions

EU patent regime 181–2, 185, 188, 191, 193–4, 196–206, 218–19, 299

TRIPS protections 29–31, 126, 307

recombinant DNA 2–3, 59–61

Red Doves patent application 213–14

Relaxin case 220–22, 227–8

reproductive cloning 94, 100–104, 106–8

Rifkin, J. 174, 298, 304

right to life

EU position on 80–81, 300

stem cell research, and 83–4, 88–9, 91–2, 133

RNA (ribonucleic acid) 57

Roe v. Wade 79–80, 129–30, 170

Safe Harbor Principles, proposal 308–9

Sgreccia, E. 172–3

Shell Development Co. v. Watson 137, 139

Shirley v. Sibelius 79, 89, 134, 173

somatic cells 62–3

Spain

stem cell research restrictions 83, 90, 303

statute of the human embryo see human embryos

stem cells

aborted foetuses, from 92

adult stem cells 86–7, 92

amniotic stem cells 86


biopsy, by 90–91

bone marrow 86–7

characteristics 85

cloning 91–2, 94–5, 105

communal or industrial purposes 239–40

dead embryos, from 90–92, 133

defective embryos, creation of 135

diagnosis or therapy uses 62–84, 87–8, 90–91

embryoid bodies, from 90–91

embryonic stem cells 86–7, 130–32, 169–73, 230–42

destruction of embryos 131, 234–6, 240

patent cases 169–73, 230–42

regulatory restrictions 230–32, 234–6

extraction 90–92, 135

foetal stem cells 86, 92

frozen embryos 169–70

gene therapy 63–5

human dignity of embryo, and 76–7, 88–9, 238–9
Index

industriality/utility requirement, and 25–6
informed consent 92, 133, 135
patent cases
   EU 230–42
   US 169–73
pluritopotency 234–5, 241–2
regulatory restrictions
   Dickey-Wicker amendment 78–9, 89, 134, 173
   EU 80–84, 89–90, 230–32, 234–6
   right to life, and 83–4, 88–9, 91–2, 133
somatic cell reprogramming, and 90–91
therapeutic cloning 91–2, 94–5, 105
totipotency 86, 130
types and uses 85–7, 130, 132
umbilical stem cells 86, 92
surgical methods
   patent exclusions 31, 126
therapeutic cloning 94–5, 104–7
tragedy of anticommons 251–2, 284–5
Transatlantic Trade and Investment Partnership (TTIP) 306
transgenic organisms, patentability 3, 53, 83–4, 124–5, 174, 298
Treaty on Deposit of Microorganisms for Patent Procedures (1977) 32–3
TRIPS Agreement
   amendment proposals 308–9
   background 14
   compulsory licensing 287–8
Directive on Biotechnological Inventions, compared 190–91
implementation, national approaches 33–5
importance 34, 264, 286–7, 306–8
patentability
   animal and plant exceptions 29–30, 32
   biotechnology, failure to mention 33–4
   exclusions 29–31, 126
experimental use exception 286–7
of life 126
morality, and 126, 307–8
non-discrimination requirement 29–30
plant varieties 31–2
process protections 32
product of nature doctrine 33, 196
public health exception 29–31, 287, 308
public order exception 29–31, 126, 287, 307
scope and limitations 29–34
principles 18–19
purpose 14
scope and limitations 29–34
unborn child see human embryos
United Kingdom
   DNA patent cases 222–3
   stem cell research restrictions 82–3, 90
United States
   bioethics
      advisory organizations 131–2, 267–8
      animal life, patentability of 49, 53–4, 142–4, 165–7
      embryo manipulation 128–9
      embryonic stem cells 169–73
      genetic material and human cells, patentability 167–75
      human cloning 173–5
      human organs, marketing 130
      investigative institutions 128–9
      microorganisms, patentability of 165
      regulatory development 129
   biotechnological inventions
      compatibility clauses 118
      composition of matter, as 137, 139–40
      moral utility doctrine 122–6
      patent regime relevance to 111, 116–19
      technology transfer 118
   biotechnology industry
ethical guidelines 127–8
growth and importance 109
human cloning
bioethics of 95–7, 173–5
ethical guidelines 127–8
patent cases 173–5
regulatory restrictions 98–9, 103–4, 119, 173–5
human dignity
constitutional protection of 119–20, 174–5
human embryos
dignity and legal status of 72–3, 79–80
embryo manipulation 128–9
Government authorized research 172–3
patent cases 169–73
right to life 129, 133
patent cases
animals, patentability of 142–4, 165–7
composition of matter,
interpretation 137, 139–40
embryonic stem cell research 169–73
genetic sequences, patentability of 148–52
genetic treatments and tests,
patentability of 154–64
human cloning 173–5
human DNA, patentability of 145–75
immoral patents 120–21
importance of 111–14, 136, 266–7, 271–3
interpretation role 111–14, 136
isolation and incorporation processes, patentability of 153–64, 210
isolation, purification and manufacture, interpretation 137–41
microorganisms, patentability of 136–41, 165
patent regime, role in development 111–14
product of nature doctrine 138–41, 161–4, 276–81
utility requirement 122–6, 149–51
patent regime
ad hoc basis for 265
advisory bodies, influences of 266–8
amendments 114, 116–19, 137
animals, patentability of 31, 142–4, 165–7
application evaluation processes 272
background 36–7, 112–15
biotechnology, patent limitations 282–3, 304–6
biotechnology, relevance to 111, 116–19, 304–5
case law role in 111–14, 136, 266–7, 271–3
compulsory licensing, and 287
Congress, influences of 304–5
constitutional basis 17, 35, 110, 112–13, 119, 174–5
development, influences on 265–6, 269–73, 304–5
disclosure requirement 27–9, 115
EU regime, differences from 35–7, 110–11, 121, 263–74, 293, 305–6
exclusions 35, 111, 126, 248
forum shopping, and 116–17
genetic patent guidelines 8
harmonization 116–17
human cloning 119, 174–5
industrial/utility requirement 25, 115, 121–6
interest groups, influences of 269–73
interpretation guidelines 280–81, 283–4
invention vs. discovery 7, 19–20
isolated or purified materials 276–7
limitations 113, 282–3, 304–5
living organisms, and 117–19, 136–41
microorganisms, patentability of 136–41, 165
morality, influence of 36–8, 120–26, 298, 304–6
novelty requirement 115
originality requirement 24, 115–16, 255
ownership limitations 248
patent authorities 35
patentability, characteristics of 111, 114–17, 120, 136
political influences on 265, 269–73, 275
principles 35–6, 110–11, 114–15
product of nature doctrine 138–41, 161–4, 276–81
purpose 110, 112–13, 140
Sensitive Application Warning System 298
technology transfer 118
time limits 17
utilitarian approach 295, 305
stem cells
bioethics, and 169–73
defective embryos, creation of 135
Dickey-Wicker amendment 78–9, 89, 134, 173
ethical guidelines 132–4
Government authorized research 172–3
patent cases 169–73
TRIPS Agreement
implementation approach 34–5
influences 126

Universal Declaration on the Human Genome and Human Rights (1997)
on common heritage of mankind 296–7
human cloning, and 97–8
on human dignity 77, 97–8, 211
human genome research 67–70, 127–8, 277, 296–7
influences of 211–12, 267
principles 211–12
University of Utah patent applications 228–9
unpatentable innovations
diagnostic/surgical methods 31, 126, 195, 199, 229
DNA exclusions 32–3
EU patent regime 188–90, 193, 199–200, 206–7
transgenic humans/chimeras 53, 83–4, 124–5, 174, 298
TRIPS Agreement exclusions 29–31, 126
Upjohn’s Application 225–6
utilitarianism 51–2, 73, 295, 304–5
utility requirement 18, 24–6
EU patent regime 25, 179–80, 206–9
gene sequences 149–50, 207–9
moral utility doctrine 122–6
US patent regime 115, 121–6, 149–51

WARF patent application 170–71, 233–4, 306
Wisconsin Alumni Research Foundation patent application 232–6